InflaRx N.V.
NASDAQ:IFRXBiotechnology
Healthcare
$1.09 -0.82%
-$0.02 today
- Market cap
- $160.63M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
52W Low $0.74High $2.95
Volume 0.66M
Average 1.80M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$33.92M
FY 2025 · Annual
Investing Cash Flow
$3.11M
FY 2025 · Annual
-94.1% YoYFinancing Cash Flow
$32.00M
FY 2025 · Annual
+8181.0% YoYCash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (43.83M) |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 402.93K |
| Deferred Income Tax | 1.16M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.33M | 6.04M | 3.41M | 4.07M | 0 |
| Change in Working Capital | 1.54M | (9.77M) | 1M | (2.28M) | 4.66M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 2.12M |
| Inventory | 0 | 0 | (11.37M) | 4.47M | 6.63M |
| Accounts Payables | 316.11K | (3.52M) | 0 | 0 | (5.76M) |
| Other Working Capital | 1.22M | (6.25M) | 12.37M | (6.75M) | 1.68M |
| Other Non-Cash Items | (2M) | (1.13M) | (131.29K) | (4.76M) | 4.84M |
| Operating Cash Flow | (39.94M) | (33.74M) | (37.81M) | (48.56M) | (33.92M) |
| Capital Expenditures | (37.78K) | (162.39K) | (81.1K) | (46.87K) | (111.13K) |
| Acquisitions (Net) | 37.78K | (19.52M) | 0 | 0 | 0 |
| Purchases of Investments | (97.52M) | (64.47M) | (104.05M) | (35.34M) | (44.28M) |
| Sales of Investments | 71.6M | 84M | 86.44M | 87.75M | 47.5M |
| Other Investing Activities | (37.78K) | 19.52M | 0 | 1 | (3) |
| Investing Cash Flow | (25.95M) | 19.36M | (17.7M) | 52.36M | 3.11M |
| Debt Repayment | (360.64K) | (364.43K) | (373.98K) | (388.11K) | (357.58K) |
| Common Stock Issued | 65.14M | 2.35M | 56.48M | 1.1M | 32.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.2M) | (47.74K) | (3.12M) | (323.73K) | 14.11K |
| Financing Cash Flow | 61.58M | 1.94M | 52.99M | 386.45K | 32M |
| Effect of Forex Changes | 4.59M | 2.46M | (974.1K) | 1.41M | (1.37M) |
| Net Change in Cash | 281.31K | (9.98M) | (3.5M) | 5.61M | (179.66K) |
| Free Cash Flow | (39.97M) | (33.91M) | (37.89M) | (48.6M) | (34.03M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$43.8M
+ D&A$402.9K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$4.7M
+ Other Non-Cash$4.8M
= Operating Cash Flow-$33.9M
- Capex-$111.1K
= Free Cash Flow-$34.0M
Analysis
FY2025 free cash flow is -$34.0M. FCF conversion is 77.6% of net income. Operating cash flow was -$33.9M, with capex of -$111.1K. The largest bridge item is Other Non-Cash at $4.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Aug 17, 2026 |
Does IFRX generate free cash flow?
InflaRx N.V. (IFRX) generated -$34.03M of free cash flow in fiscal 2025.
How much operating cash flow does IFRX produce?
Operating cash flow was -$33.92M, before capital expenditures of $111,127.00.
Continue the stock analysis
Jump to another research area for this company.